Pfizer shares are trading in the mid-$20s as investors grapple with a critical question: is this battered pharmaceutical giant destined to remain stuck in neutral, or does its aggressive push into obesity drugs and oncology successes position the company for a surprising rebound? The answer may hinge on three major obesity-related deals that could reshape […]

The postPfizer stock surge depends on risky $10B obesity gambleappeared first onRolling Out.